

WEALTH WEEKLY Weekly Alerts You Can Use!

Weekly View: Nifty, Bank Nifty:

Indices	СМР	Support	Resistance	50 DMA	200 DMA	Range	Preferred Trade
NIFTY	16584	16001	16837	16870	17269	16101- 16837	Sell at CMP. Targets at 16301/ 16001/15775. Stop at 16901.
BANK NIFTY	35275	33751	37001	35733	36842		Sell at CMP. Targets at 34201/33751/32901. Stop at 36751.

Medium Term Pick:

Stocks	СМР	Support	Resistance	50 DMA	200 DMA	Bias	Preferred Trade
BIOCON	320	275	357	331	357	Negative	BIOCON deserves attention as the stock is signaling a breakdown from a probable higher consolidation zone on the daily charts. Amidst deteriorating technical conditions, the stock is likely to stage massive corrective declines in near/medium term. Establishing short positions at CMP, and on strength between 341-345 zone should be the preferred trading strategy, targeting 300 mark and then aggressive targets at 275-281 zone. Stop above 357. Holding Period: 1-2 Months.

Incorporated in the year 1978, **Biocon Ltd.** is an Indian biopharmaceutical company that caters in discovering, developing and producing biologics in chronic therapies. Biocon produces anti diabetic agents like Acarbose, Pioglitazone, Repaglinides & Rosiglitazone. In the biological segment they produce Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase & Monoclonal Antibodies. In generics segment, Biocon is amongst the world's largest manufacturers of immunosuppressant and statin APIs. The company also produces & markets a mix of specialty & industrial enzymes for industries like paper, brewing, beverages, food, brewing, textiles & distilling.

- # Biocon's drug revenue breakup as on FY22: Biosimilars (41%), Generics (28%), CRAMS (31%).
- # Biocon now commands a market cap of Rs 38,455 Crores.
- # The biggest negative catalyst surrounding Biocon is that the technical landscape has deteriorated significantly on the medium term charts.
- # Technically, Biocon's stock price pattern appears ugly at current levels.
- # Firstly, overbought technical conditions still prevail on the monthly charts on backdrop of a bearish engulfing pattern on the monthly charts. The recent sequence of lower high/low is quite evident on the monthly and weekly time frames. The momentum oscillators are seen shifting in sell mode signaling further sharp corrective down move. The stock price is signaling a massive break down from a "higher consolidation zone" on the weekly charts —— confirmation of the same below 315 mark. Immediate downside risk below a 315 close is at psychological 300 mark.
- # The 200-DMA of the stock is around 357 levels.

Establishing short positions at CMP, and on strength between 341-345 zone should be the preferred trading strategy, targeting 300 mark and then aggressive targets at 275-281 zone. Stop above 357. Holding Period: 1-2 Months

Daily Chart of BIOCON:



Mehta Equities

903 Lodha Supremus, Dr. E Moses Road, Worli Naka, Mumbai - 400 018 Board: +91-22-61507100/101 Fax: +91-22-61507102